Lite Strategy (LITS) Depreciation & Amortization (CF) (2010 - 2024)
Lite Strategy (LITS) posted quarterly Depreciation & Amortization (CF) of $368000.0 for Q3 2024, up 322.99% year-over-year from $87000.0 in Q4 2023, and up 194.4% quarter-over-quarter from $125000.0 in Q2 2024.
Lite Strategy (LITS) Depreciation & Amortization (CF) (2010 - 2024) Analysis & Trends
Lite Strategy's Depreciation & Amortization (CF) history runs 15 years deep, the most recent figure standing at $368000.0 for Q3 2024.
- In Q3 2024, Depreciation & Amortization (CF) rose 322.99% year-over-year to $368000.0; the TTM figure through Jun 2025 stood at $368000.0 (down 3.92% YoY), while the FY2025 annual figure was $368000.0, down 3.92% from the prior year.
- Depreciation & Amortization (CF) for Q3 2024 stood at $368000.0, up from $125000.0 in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $368000.0 in Q3 2024, with the low at $19000.0 in Q2 2020.
- The 5-year median for Depreciation & Amortization (CF) is $85000.0 (2022), against an average of $94578.9.
- The sharpest annual moves came in 2020 and 2024: Depreciation & Amortization (CF) sank 32.14% in 2020, then soared 322.99% in 2024.
- Lite Strategy's Depreciation & Amortization (CF) stood at $74000.0 in 2020, then increased by 1.35% to $75000.0 in 2021, then advanced by 22.67% to $92000.0 in 2022, then dropped by 7.61% to $85000.0 in 2023, then surged by 332.94% to $368000.0 in 2024.
- Business Quant data shows LITS's Depreciation & Amortization (CF) at $368000.0 in Q3 2024, $125000.0 in Q2 2024, and $86000.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Lite Strategy | 35.71 Mn | 28.17 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 368,000.00 |
| Sep 30, 2024 | 368,000.00 |
| Jun 30, 2024 | 125,000.00 |
| Jun 30, 2024 | 125,000.00 |
| Mar 31, 2024 | 86,000.00 |
| Mar 31, 2024 | 86,000.00 |
| Dec 31, 2023 | 85,000.00 |
| Dec 31, 2023 | 85,000.00 |
| Sep 30, 2023 | 87,000.00 |
| Sep 30, 2023 | 87,000.00 |
| Jun 30, 2023 | 98,000.00 |
| Jun 30, 2023 | 98,000.00 |
| Mar 31, 2023 | 97,000.00 |
| Mar 31, 2023 | 97,000.00 |
| Dec 31, 2022 | 92,000.00 |
| Dec 31, 2022 | 92,000.00 |
| Sep 30, 2022 | 99,000.00 |
| Sep 30, 2022 | 99,000.00 |
| Jun 30, 2022 | 85,000.00 |
| Jun 30, 2022 | 85,000.00 |